Laboratory

Discover our products

Clinical

Discovers our solutions

2 nouveaux établissements équipés avec CeGInaDis

Jun 16, 2017

Fédialis Médica a le plaisir de vous informer que les hôpitaux de la Pitié-Salpêtrière à Paris, ainsi que le CHU de Fort de France en Martinique utilisent notre logiciel CeGInaDis (version CeGIDD du logiciel NADIS) pour leurs activités de routine CeGIDD.
Read more
ABL Announces Distribution Agreement with BADER SULTAN & BROTHERS CO W.L.L

Jun 09, 2017

Advanced Biological Laboratories (ABL) S.A. and BADER SULTAN & BROTHERS CO W.L.L are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Kuwait. See current channel partners.
Read more
In June Save Up to 20% on all DeepChek® Assays for HIV and HCV

May 31, 2017

I’m interested!
Read more

Annonce d’un nouveau partenariat AFRAVIH – Fédialis Médica

May 23, 2017

Fédialis Médica a le plaisir de vous informer de la signature d’un partenariat avec l’AFRAVIH (www.afravih.org/) dans le but de tester l’utilisation du dossier médical informatisé NADIS pour le suivi et la prise en charge de patients vivant avec une pathologie chronique (VIH, hépatite, t…
Read more
SEQHEPB V6 – The Largest HBV Interpretation System & Database

May 17, 2017

ABL is pleased to announce the official release of its SeqHepB v6 interpretation system & database. Dedicated to the management of Viral Hepatitis B (HBV) sequencing data, the software can handle Capillary Electrophoresis or Next Generation Sequencing data, performs genotyping and mutation detec…
Read more
Renewal and Extension of the partnership with ThermoFisher around virology genotyping.

May 02, 2017

ABL is pleased to announce the renewal and the extension of the Reseller rights given to ThermoFisher to promote ABL’s Capillary Electrophoresis sequencing data analysis software (ViroScore®), on a worldwide basis (except Spain). The platform is intended to be used for genotyping in Vir…
Read more

Studies on DeepChek®-HCV Assays presented at the EASL 2017

Apr 24, 2017

“Evaluation of a sequence-based method for hepatitis C genotyping (DeepChek® SingleRound PCR and NS5B/5’UTR sequencing) and comparison with VERSANT HCV Genotype 2.0 assay (InnoLiPA)” – Greet J. Boland et al. – EASL 2017 – See poster “Retreatment with Direct…
Read more
New patent issued in Hong Kong around HBV resistance announced!

Apr 11, 2017

Advanced Biological Laboratories has been granted additional patents in Hong Kong (HK1121187) to further protect its intellectual property and reinforce the already existing core patent entitled ” Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications th…
Read more
ABL Welcomes You at the EASL in Amsterdam (April 19th – 22nd 2017)

Apr 11, 2017

Our team will provide information on our portfolio: Laboratories, virologists and microbiologists: DeepChek® Assays (Genotyping & Drug Resistance) UltraGene® Assays (Viral Load Detection) DeepChek®, SeqHepB® (Software systems for Sanger or NGS sequencing data management) Application: HBV, HCV… C…
Read more

Latest updates on ABL’s HIV Assays Portfolio

Apr 05, 2017

ABL is delighted to announce the outcomes of a National Quality Control Study performed on the DeepChek® HIV Assays (RT/PR and INTEGRASE) on a panel human plasma samples collected in 2015 in 56 different labs in France. The overall agreement in the detection of HIV virus mutations exceeded 99% compa…
Read more
Technogenetics to Offer ABL’s Genotyping Products in Italy

Jan 30, 2017

Advanced Biological Laboratories (ABL) S.A. and Technogenetics (TGX) today announced that they entered into an exclusive distributor agreement of the DeepChek® SingleRound Assay and software product lines in Italy. The DeepChek® SingleRound Assay product line combines target-specific PCR reagents wi…
Read more
ABL acquires Fedialis Medica

Jun 24, 2016

ABL continues developing its technology offer with Nadis(r) technology as a specialized patient management system. Nadis is widely used in France, this completes the offer for the French market in plus of microbiology reagents and software.
Read more

New Diagnostics Test and Technology for Hepatitis C

May 17, 2016

ABL inked an agreement with Inserm on a test and related IP and know-how intended for viral hepatitis C.
Read more
Combining Ion Torrent sequencing systems and the DeepChek Suite Software

Apr 18, 2016

ABL is pleased to invite you to attend the viral typing webinar held with Thermo Fisher Scientific about the combination of their next generation sequencing systems and the ABL DeepChek downstream analysis software, for HIV, HBV and HCV. Tuesday, 10th May 2016 — 5 pm CET / 4 pm GMT / 11 am EST Regis…
Read more
New commercial agreement for ViroScore® and DeepChek®

Mar 31, 2016

ABL inked a distribution agreement with Thermo Fisher Scientific for ViroScore and DeepChek, downstream analysis softwares for Sanger and Next Generation Sequencing respectively. These are also available on Thermo Fisher Cloud. See the press release.
Read more

ABL Group launches early access program

Jul 15, 2015

ABL group is pleased to announce the launch of an early access program (EAP) of its first genotyping DeepChek® assay for HCV NS5B. Further reagents will come soon to complete ABL Group’s offer for Sanger and Next Generation Sequencing. These reagents will be completed with data analysis software, Vi…
Read more
A methodology to help doctors choosing the most efficient treatment for hepatitis C

Feb 16, 2015

Barcelona, 16th February 2015. Researchers from Vall d’Hebron Research Institute (VHIR) have developed a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to…
Read more
Extension of DeepChek®-HIV portfolio with the use of PyroVir software

Jan 26, 2015

Advanced Biological Laboratories (ABL) S.A., today announced the signing of an exclusive worldwide license for commercial use of the PyroVir software and related knowledge database and know-how with the French National Institute of Health and Medical Research (Inserm) subsidiary, Inserm Transfert SA…
Read more

HepatiC® trademark registration

Jan 20, 2015

ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252. The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antivira…
Read more
ABL signs agreement with UH Case Medical Center to offer HIV drug resistance tests

Jan 13, 2015

University Hospitals (UH) Case Medical Center has signed an agreement with Advanced Biological Laboratories (ABL), to join efforts on the designing and validation of an HIV drug resistance and tropism assay based on next-generation sequencing (NGS). See the press release. See the press release. http…
Read more
DeepChek®-HBV and HCV Now Available in Illumina’s BaseSpace Apps

Jan 05, 2015

Two new DeepChek® applications dedicated to viral hepatitis B (HBV) and hepatitis C (HCV) are now available in BaseSpace, the Illumina’s dedicated applications store and cloud-based informatics community dedicated to advancing genomic analysis. See the press release about BaseSpace and Illumina.
Read more

ABL@ Illumina BaseSpace Worldwide Developers Conference (WWDC)

Nov 17, 2014

ABL will be participating to the next Illumina BaseSpace Worldwide Developers Conference (WWDC) in San Francisco on the 8th and 9th of December 2014. View more
Read more
Initiation of a collaborative tuberculosis project

Oct 22, 2014

ABL S.A, The University of Hong Kong and The Hong Kong Polytechnic University are launching their collaborative tuberculosis (TB) project to develop a deep-sequencing assay and its tailored bio-informatics pipeline. View more
Read more
Collaboration on HBV genomic variations and HCC

Oct 13, 2014

ABL is pleased to announce a new collaboration with the New Zealand Liver Transplant Unit and LabPlus at Auckland City Hospital. This will evaluate the susceptibility to develop Hepatocellular Carcinoma (HCC) during 30 years follow-up, based on key baseline genomic variations of HBV in a large cohor…
Read more

ABL and Mayo Medical Laboratories Ink Collaboration and Licensing Agreements

Sep 02, 2014

ABL and Mayo Medical Laboratories will develop novel innovative LDT and related IT in the field of virology. More details available here.
Read more
Renewal and extension with Roche Diagnostics International

Aug 19, 2014

Advanced Biological Laboratories (ABL) and Roche Diagnostics International renew and extend their collaboration agreement to promote their Next-Generation Sequencing, Genotyping and Drug Resistance Products. See the full press release.
Read more
DeepChek®-HIV Now Available in Illumina’s BaseSpace Apps

Aug 19, 2014

First virology application on BaseSpace to deal with HIV next generation sequencing coming from Illumina’s platforms. See the press release about BaseSpace and Illumina.
Read more

Exclusive licensing agreement with CRP-Santé for “COMET” software

May 20, 2014

ABL entered into an exclusive worldwide licensing agreement with CRP-Santé for its COMET software designed for high performance DNA sequencing analysis and classification.See full Press Release.
Read more
ABL acquires Evivar Medical Assets and further enhances its IT Solutions and Personalized Healthcare Platform for Hepatitis B, Hepatitis C and HIV Infections

Jun 10, 2013

Read more

Laboratory

Clinical

Newsletter